Want to see ELTX full AI Analyst Report?
ELTX Stock Chart & Stats
$3.00
$0.02(0.67%)
At close: 4:00 PM EDT
$3.00
$0.02(0.67%)
Day’s Range― - ―
52-Week Range$2.66 - $16.00
Previous CloseN/A
Volume163.39K
Average Volume (3M)3.31M
Market Cap
$80.82M
Enterprise Value$65.91
Total Cash (Recent Filing)$23.48M
Total Debt (Recent Filing)$14.15M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding26,281,881
10 Day Avg. Volume474,004
30 Day Avg. Volume3,311,596
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.67Price Target Upside588.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Potentially Differentiated Immunotherapy PlatformComplete responses after ELI-002 7P followed by nivolumab, alongside persistent KRAS-specific T-cell responses, suggest the AMP platform may prime tumors for checkpoint therapy. If confirmed prospectively, this could differentiate Elicio in a high-unmet-need cancer setting.
Biological Activity And TolerabilityThe reported link between immune responses and improved outcomes supports the platform’s biological rationale, while favorable safety and fewer adverse events could help sustain patient enrollment and combination development in later-stage trials.
Additional Development FundingThe financing increases resources for advancing ELI-002 7P and generating combination-study data. Near-term capital supports clinical execution and may help the company reach meaningful development milestones before seeking additional strategic funding.
Bears Say
No Commercial RevenueElicio has no approved commercial product and therefore lacks recurring product revenue. Continued losses without operating revenue leave the company dependent on clinical progress, partnerships, or capital markets to fund its business.
Persistent Cash Burn And Funding DependenceSustained cash consumption materially limits financial flexibility and can force recurring equity or debt financing. This creates dilution and execution risk, particularly as Elicio funds multiple clinical programs without product cash generation.
Phase 2 Primary Endpoint FailureMissing the primary endpoint weakens the evidence base for ELI-002 7P and raises regulatory and development risk. Post-hoc subgroup findings may support a refined Phase 3 design, but they require prospective confirmation and could lengthen or complicate approval.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics, Inc’s price range in the past 12 months?
Elicio Therapeutics, Inc lowest stock price was $2.66 and its highest was $16.00 in the past 12 months.
What is Elicio Therapeutics, Inc’s market cap?
Elicio Therapeutics, Inc’s market cap is $80.82M.
When is Elicio Therapeutics, Inc’s upcoming earnings report date?
Elicio Therapeutics, Inc’s upcoming earnings report date is Mar 26, 2027 which is in 215 days.
How were Elicio Therapeutics, Inc’s earnings last quarter?
Elicio Therapeutics, Inc released its earnings results on Aug 13, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.538 by $0.108.
Is Elicio Therapeutics, Inc overvalued?
According to Wall Street analysts Elicio Therapeutics, Inc’s price is currently Undervalued.
Does Elicio Therapeutics, Inc pay dividends?
Elicio Therapeutics, Inc does not currently pay dividends.
What is Elicio Therapeutics, Inc’s EPS estimate?
Elicio Therapeutics, Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elicio Therapeutics, Inc have?
Elicio Therapeutics, Inc has 26,281,881 shares outstanding.
What happened to Elicio Therapeutics, Inc’s price movement after its last earnings report?
Elicio Therapeutics, Inc reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.538. Following the earnings report the stock price went down -1.905%.
Which hedge fund is a major shareholder of Elicio Therapeutics, Inc?
Currently, no hedge funds are holding shares in ELTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (588.89% Upside)
$20.67 (588.89% Upside)
Blogger Sentiment
Neutral
ELTX Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 12.0%
Last 30 Days ▲ 12.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Company Description
Elicio Therapeutics, Inc
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$20.67
▲(588.89% Upside)
Technical Analysis
Compugen
―
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―
Ownership Overview
0.85% Insiders
2.40% Mutual Funds
6.82% Other Institutional Investors
85.56% Public Companies and
Individual Investors